Antibiotics for treating ventilator-associated pneumonia in adult patients
Citation: Arthur LE, Kizor RS, Selim AG, et al. Antibiotics for ventilator-associated pneumonia. Cochrane Database of Systematic Reviews 2016; (10): CD004267
What is this? Some patients with COVID-19 will develop respiratory failure and need help with their breathing. This might be provided by mechanical ventilation (MV) in an intensive care unit (ICU), but this can cause complications, including ventilator-associated pneumonia (VAP). Antibiotic therapy is used to treat VAP.
In this Cochrane systematic review, the authors searched for randomized trials comparing different antibiotic treatments of VAP in adult patients. They did not apply any language or type of publication restrictions and did their main searches in December 2015. They identified 12 studies (3571 participants).
What works: Single and combination antibiotic therapies have similar effects on all-cause mortality for adult patients with ventilator-associated pneumonia.
Carbapenem and non-carbapenem therapies have similar effects on all-cause mortality for adult patients with ventilator-associated pneumonia.
What doesn’t work: Not noted.
What’s uncertain: It is uncertain which antibiotic regimen is best for treating ventilator-associated pneumonia.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.